US Stock MarketDetailed Quotes
IMNN Imunon
- 0.693
- +0.009+1.32%
Close Nov 21 16:00 ET
- 0.695
- +0.002+0.26%
Post 20:01 ET
10.05MMarket Cap-362P/E (TTM)
0.699High0.640Low237.13KVolume0.664Open0.684Pre Close158.13KTurnover1.72%Turnover RatioLossP/E (Static)14.50MShares3.65052wk High1.23P/B9.56MFloat Cap0.48052wk Low--Dividend TTM13.79MShs Float145293.750Historical High--Div YieldTTM8.57%Amplitude0.480Historical Low0.666Avg Price1Lot Size
Imunon Stock Forum
Sign in to post a comment
$Imunon (IMNN.US)$ lol pr today is target price cut from 14 to 12 dollars, while this ish has been trading at .80 cents.
1
$Imunon (IMNN.US)$
2025
LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 (IL-12) immunoth...
2025
LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 (IL-12) immunoth...
1
$Imunon (IMNN.US)$
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
IMUNON announced positive Phase 2 OVATION 2 trial results for IMNN-001 in advanced ovarian cancer. The study of 112 patients showed that IMNN-001 plus standard chemotherapy improved overall survival by 35% (40.5 vs 29.4 months) and progression-free survival by 25% (14.9 vs 11.9 months) compared to chemotherapy alone. The treatment demonstr...
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
IMUNON announced positive Phase 2 OVATION 2 trial results for IMNN-001 in advanced ovarian cancer. The study of 112 patients showed that IMNN-001 plus standard chemotherapy improved overall survival by 35% (40.5 vs 29.4 months) and progression-free survival by 25% (14.9 vs 11.9 months) compared to chemotherapy alone. The treatment demonstr...
1
$Imunon (IMNN.US)$ bro drop the pr, we need that to move upward
1
$Imunon (IMNN.US)$ tomorrow catalyst, be ready
2
5
$Imunon (IMNN.US)$ Lets go
1
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
tian liang : The target should be lowered to $2.